Seeking Alpha

BioCryst (BCRX) is withdrawing its Investigational New Drug application for the antiviral...

BioCryst (BCRX) is withdrawing its Investigational New Drug application for the antiviral nucleoside, BCX5191, following discussions with the FDA. The agency indicated patient safety concerns over the preclinical toxicity profile of the drug at exposure levels which they believe are likely to be necessary to reduce the viral load in patients infected with the hepatitis C virus.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)